The extent of genetic influence in the aetiology of gestational hypertension has not been completely determined. The aim of this study was to analyse the relationship between aldosterone levels and the -344T/C polymorphism of the aldosterone synthase gene (CYP11B2) and to investigate the frequency of the S810L mutation of mineralocorticoid receptor (MR) in gestational hypertension. One hundred women with pregnancy-induced hypertension and 100 with normal pregnancy were studied to measure serum aldosterone and progesterone levels and for the genotypification of the -344T/C polymorphism of CYP11B2 gene and the S810L mutation of MR by RFLP-PCR and SSP, respectively. Serum aldosterone levels were reduced (o0.000001) and serum progesterone levels increased (o0.000001) in gestational hypertensive women as compared with normal pregnant women. The -344T/C of CYP11B2 genotypic frequencies were similar in the hypertensive and normotensive pregnant women. The 810L-mutated allele of MR was found in 12% of the hypertensive and 9.4% of the normotensive pregnant women. In contrast to the observations made in preeclampsia, the genotype of -344T/C of CYP11B2 was neither related with gestational hypertension nor with aldosterone levels at delivery. The frequency of the S810L mutation was similar in the hypertensive and normotensive women but higher than observed in other reports.
Introduction
Hypertensive disorders of pregnancy affect up to 8% of all gestations and represent a major cause of maternal and neonatal mortality in the United States. 1 In Mexico, their prevalence ranges from 7 to 10%. 2 The pathophysiology of these disorders is not clear, but a familial predisposition has been found for preeclampsia and gestational hypertension. 3, 4 Low plasma volume expansion, reduced cardiac output and increased total peripheral vascular resistance have been described in nearterm pregnant women with preeclampsia. This low plasma volume expansion precedes aldosterone and estradiol diminution. [5] [6] [7] The renin-angiotensinaldosterone system and estrogens are considered primary modulators of plasma volume expansion during pregnancy. 8 Although plasma aldosterone concentration is reduced in hypertensive pregnant women, the aldosterone-renin ratio is twofold larger than in normal pregnancy, and it may be another manifestation of increased adrenal sensitivity to angiotensin II. 9 Therefore, one key player in the control of hypertension during pregnancy may be aldosterone synthase (CYP11B2) and the control of CYP11B2 expression may be responsible for hypertension. 6 This single nucleotide polymorphism is located in the CYP11B2 promoter within a putative binding site for the steroidogenic factor-1. Earlier reports have examined the relationship of -344T/C CYP11B2 with essential hypertension in diverse populations, with different results. In Japanese hypertensive patients, the C allele is more frequent, 10 whereas the T allele was associated with hypertension in British Caucasians. 11 Furthermore, the C allele, and TC, TT genotypes have been associated with elevated aldosterone levels, 12, 13 and the T allele with increased aldosterone-renin ratio in hypertensive subjects.
14 Non-hypertensive subjects, carriers of the T allele or TT genotype have high plasma aldosterone levels 15, 16 and TT homozygotes show augmented systolic blood pressure with increasing age. 17 The studies on the association of this CYP11B2 gene polymorphism with gestational hypertension or preeclampsia are scant and remain controversial. Vasconcelos et al. 18 did not find a significant association between the -344C/T polymorphism and gestational hypertension or preeclampsia, whereas Escher et al. 19 found that the -344C/T genotype is increased, and the -344T/T genotype distribution is lower in the preeclamptic women as compared with normal pregnant women. Percin et al. 20 studied women with preeclampsia, eclampsia and the HELLP syndrome and found that the CYP11B2 gene polymorphism is not directly associated with these conditions.
The mineralocorticoid receptor (MR) is also important for pregnancy hypertension. Geller et al. 21 reported that an S810L mutation in MR causes early onset hypertension that is markedly exacerbated at pregnancy. This substitution results in constitutive MR activity and alters receptor specificity. Thus, antagonists of the wild-type MR (MR wt ), such as progesterone and other steroids lacking 21-hidroxyl group, are potent agonists for the mutated MR (MR L810 ). 21 Aldosterone activates both receptor forms, whereas other steroids such as progesterone display antagonist properties when bound to MR wt but can activate MR L810 . Therefore, the 100-fold progesterone increase during pregnancy may contribute to exacerbate hypertension in MR L810 carriers. 21 It is noteworthy that two other studies, one in pregnancy-induced hypertension 22 and another in essential hypertension 23 failed to detect the mutation.
In this study, we analysed the relationship of aldosterone levels with the -344T/C polymorphism of CYP11B2, and investigated the frequency of the S810L mutation of MR in women with gestational hypertension and with normal pregnancy.
Subjects and methods

Subjects
We included 100 women with normal pregnancy and 100 with diagnosis of gestational hypertension. The study was approved by the Institutional Ethics Committees of the Mexican Social Security Institute and the Department of Medical Sciences, University of Guanajuato. All patients were recruited from the Gynecology-Pediatry Hospital Unit 48, of the Mexican Social Security Institute, León, Guanajuato, Mexico, after signing an informed consent. Gestational hypertension was defined as a systolic blood pressureX140 mm Hg and/or a diastolic blood pressureX90 mm Hg on at least two occasions in an interval of X6 h, after the 20th week of gestation in women known to be normotensive before pregnancy and before 20 weeks of gestation. 24 An obstetric clinical history was obtained, including familial history of gestational hypertension, essential hypertension and diabetes mellitus. Standing and recumbent arterial blood pressure were taken as the mean of three measurements at the start, the middle and the end of each interview after a minimum of 5 min rest, using a mercury sphygmomanometer with a proper cuff placed on the dominant arm. The patients were hospitalized 12 h before delivery and studied after an overnight fasting. To compensate for hormone pulse variation, 2 ml blood samples were obtained through a venous catheter, every 2 min during 20 min to make a pool. Serum and plasma samples were frozen at À701C until the hormonal measurements were made. The hormonal assays included serum aldosterone, with negligible cross-reactivity to progesterone according to the manufacturer's specifications. Nevertheless, progesterone concentrations present in pregnancy did not alter the aldosterone results (Diagnostics System Laboratories, Inc., Webster, TX, USA), progesterone (Diagnostic Products Corporation, Los Angeles CA, USA), plasma renin activity (PRA) by means of a quantitative assay of angiotensin I (Diasorin, Saluggia, Italy), all of them by Radioimmunoassay. PRA was calculated as angiotensin I concentrations at 37 1C minus angiotensin I concentrations at 4 1C multiplied by 1.12/incubation hours ¼ ng ml À1 h
À1
.
Genotyping of the -344T/C CYP11B2 gene polymorphism DNA was extracted from EDTA-anticoagulated blood using a standard phenol-chloroform method and stored at À20 1C until batch genotyping. The region of DNA containing the polymorphism was amplified by PCR as reported earlier 25 with the primers: sense 5 0 -CAGGAGGAGACCCCATGTGAC-3 0 ; antisense 5 0 -CCTCCACCCTGTTCAGCCC-3 0 (Invitrogen, Life Technologies, Carlsbad, CA, USA). PCR conditions were: 35 cycles at 94 1C for 1 min, at 64 1C for 1 min and at 72 1C for 1 min. PCR products were digested with 10U HaeIII (New England BioLabs, Inc., Ipswich, MA, USA) and digestion products were analysed by agarose electrophoresis. The C-344T mutation eliminates an internal HaeIII site, resulting in a 273 bp (T allele) or 202 and 71 bp (C allele) digestion products.
Analysis of the S810L mutation of the MR We designed a PCR method using two mutationspecific forward primers containing the nucleotide present either in the wt or the mutated allele at their extreme 3 0 end (FOR1 and FOR2 primers, respectively). Primer sequences were deduced from MLR gene exon 6 sequence (accession no. AF068620). Primer sequences were: FOR1, 5
0 -CCTAATCCAGTA TTCTTGGATGTGCTTATC-3 0 ; FOR2:
The underlined nucleotide represents the wt or mutated alleles. The reverse primer was: 5 0 -CCAGTTTCAGT AGATTCTTTCACCAACG-3 0 . Each DNA sample was amplified in two separate PCR reactions containing one FOR1 and the other FOR2. PCR was conducted in standard conditions with a 59 1C annealing temperature and the resulting 224 bp product was visualized by 2% agarose electrophoresis. Genotype was assigned based on the presence of the amplification product in either one of the two reactions (wt or mutant homozygote) or in both (heterozygote). To ascertain the mutation specificity of the PCR protocol, we produced a mutated sequence in vitro by the following method. First, we synthesized a mutant sense strand by single-primer extension with the oligonucleotide 5 0 -AAATTACCCTAATCTAGTATTCT TGGATGTGCTTATTATCATTTGGCCTGAGCTGGAGA TCGTAC-3 0 (the mutation-representing nucleotide is underlined) (Invitrogen, Life Technologies) by conducting 12 1-min extensions with Taq polymerase at 72 1C and with limiting amounts (10 ng) of wt DNA as template. Second, the mutant strand was PCR amplified with 20 further cycles including the reverse primer described above and the product was purified. The resulting double-strand DNA could be amplified by the FOR2, but not the FOR1 primer as expected.
Statistical analysis
The clinical and hormonal characteristics are expressed as mean ± s.d., ratios and median (25-75 quartiles). t-Test for independent samples or MannWhitney U-test was used. Genotype frequencies were compared using w 2 -test. To examine the differences among the different genotypes of the C-344T polymorphism of the aldosterone synthase and the S810L mutation of the MR with blood pressure, aldosterone, and progesterone and plasmatic rennin activity levels, one-way analysis of variance and Kruskal-Walls test were used. A multiple regression model was made to evaluate the contribution of factors to blood pressure variability. The intra-assay variation coefficients for aldosterone, progesterone and PRA were 5, 6 and 7.4%, respectively. Analyses were carried out using a statistical package (Statistics, Statsoft Inc., Tulsa, OK, USA).
Results
Age and parity were similar for hypertensive and normotensive groups. Gestational age, frequency of previous hypertensive pregnancies, essential hypertension and diabetes mellitus were higher in the hypertensive group (Table 1) . The serum aldosterone levels and PRA were significantly lower, but serum progesterone levels were higher in hypertensive than normotensive group. The aldosterone/renin index had a trend for lower values in the hypertensive group (Table 1) .
The CYP11B2 genotype distribution in both groups of study was in Hardy-Weinberg equilibrium. The hypertensive and normotensive groups did not show a significant difference in aldosterone synthase (CYP11B2) genotype frequencies. Analysing the association of the genotypes with blood pressure and hormonal characteristics separately in hypertensive and normotensive women, we did not find any significant difference. In the normotensive group, only a marginal trend for a lower diastolic blood pressure was found in women carrying the CYP11B2 TT genotype ( Table 2) .
There was no difference in the distribution of the S810L mutation genotypes of the MR between hypertensive and normotensive group ( Table 3) . The MR L810 mutation was found in 12 hypertensive women, 5 MR S810L heterozygotes and 7 MR L810L homozygotes, whereas the MR L810 mutation was found in eight normotensive women, three MR S810L heterozygotes and five MR L810L homozygotes. In this group, only 85 DNA samples were available for genotyping. Table 3 shows that the blood pressure, the aldosterone, progesterone, PRA levels and aldosterone/renin ratio were not associated with the three MR S810L genotypes in the normotensive or the hypertensive group. In addition, we carried out a multiple regression analysis for systolic blood pressure including as candidate regressors: aldosterone, progesterone, PRA levels and aldosterone/ renin index. We found a negative correlation of aldosterone (r ¼ À0.48; Po0.00000) and PRA levels (r ¼ À0.23; Po0.0008), and a positive correlation of progesterone levels (r ¼ 0.31; Po0.00001). The correlations with diastolic blood pressure were similar: with aldosterone (r ¼ À0.52; Po0.00001), PRA (r ¼ À0.24; Po0.0006) and progesterone levels (r ¼ 0.33; Po0.000003).
Discussion
Various reports have shown the importance of genetic factors in the development of gestational hypertension, 2,3 estimating heritability for gestational hypertension in 0.24. Hypertensive women have more often a family history of preeclampsia and/or gestational hypertension, suggesting that his factor should help to identify women at risk of developing hypertension at pregnancy. 3 Although polymorphisms in the CYP11B2 promoter region gene were a likely source of aldosterone variation in the light of published data on essential hypertension, 10-13,15,16 we did not detect any significant association between the -344T/C polymorphism and gestational hypertension in Mexican women. These results are in accordance with a study made in Brazilian women with gestational hypertension and preeclampsia. 18 
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Percin et al. 20 studying Turkish women with preeclampsia, eclampsia or HELLP syndrome did not find any association with the -344T/C polymorphism.
In their study, they considered the -344T/T genotype as the wt genotype. Escher et al. 19 found that a high aldosterone availability is associated with lower C-344T CYP11B2 and S810L MR in gestational hypertension M Ramı´rez-Salazar et al maternal blood pressure, and that the -344C/T genotype is more frequent in women with preeclampsia, while the presence of the wild type (wt/wt) of the intron 2 conversion polymorphism predisposed to preeclampsia. 19 They conclude that the gain-of-function variants of the CYP11B2 reduce the risk for developing preeclampsia. 19 In contrast, the genetic polymorphism V386A in exon 7 of CYP11B2 was detected in 17% of preeclamptic women. 6 This polymorphism has been investigated in vitro and has shown to reduce, but not abrogate CYP11B2 activity in cell cultures. 26 Our negative result may be due to the presence of other single nucleotide polymorphisms in CYP11B2 associated with elevated blood pressure and not analysed by us. Alternatively, we cannot discard that our results reflect population-specific differences.
We probed for the S810L mutation associated to severe pregnancy-induced hypertension in both hypertensive and normotensive women. The frequency of the MR L810 between the two groups was not different (12% vs 9.4%) ( Table 3 ). On the other hand, Schmider-Ross et al., 22 in 38 patients with pregnancy-induced hypertension, as well as Escher et al., 19 in 48 preeclamptic women, were not able to detect the MR L810 mutation. Although those studies were inconclusive, the earlier observation that progesterone levels were significantly elevated in preeclamptic women 7 prompted us to address the MR L810 mutation frequency in hypertensive women. Progesterone has a higher affinity for MR than aldosterone, but it confers solely a low agonistic mineralocorticoid activity. 27 In the presence of the MR L810 mutation, the physiological antagonist becomes an activator of the altered MR and leads to a rise in blood pressure. 21 However, our results are not in accordance with the data presented by Geller et al., 21 who observed complete cosegregation of the mutation with early onset hypertension in one kindred. One possible reason for this discrepancy could be that our population's genetic background affects the penetrance of the MR L810 mutation, resulting in incomplete segregation between experimental groups. This may be due to the interaction with population-specific genetic variants, or significant differences in the levels of endogenous ligands affecting the mutated receptor. Another difference between our study and the one by Geller and coworkers is that we analysed women with gestational hypertension, rather than early onset, severe hypertension. A difference in the aetiology of these two forms of hypertension cannot be ruled out.
Our work confirms earlier observations stating that plasma aldosterone [5] [6] [7] 26, 28 and PRA levels 9, 28, 29 are lower, and progesterone levels 7 are higher in pregnancy-induced hypertension. Multiple regression analysis shows a negative correlation of both systolic and diastolic blood pressure with aldosterone and PRA, and a positive correlation with progesterone levels. Plasma aldosterone concentrations were substantially lower in women with preeclampsia from the 26 weeks of gestation, whereas progesterone increases at early second trimester of gestation. Pregnant women who subsequently develop preeclampsia have lower plasma volume at the beginning of the second trimester of gestation preceding the changes in aldosterone concentrations. On the other hand, progesterone values are elevated before the clinical onset of disease. 7 It has been shown that an excess of progesterone relative to estrogen antagonizes the stimulatory effects of estrogen on endothelium-dependent responses associated with NO production. 30 In accordance with the findings of Israel and Peceñ o, 28 the aldosterone/renin ratio is lower in our hypertensive group of women as compared with the normotensive group, meaning that the circulating renin-angiotensin-aldosterone system is suppressed in pregnancy-induced hypertension.
Intravascular volume depletion along with low plasma renin-angiotensin aldosterone is a characteristic of hypertensive pregnancy-associated disorders. There are two main explanations for this phenomenon. The inappropriate sensing of the vascular 'overfilling' theory states an abnormal shifting of fluid from the vascular to the extravascular compartment. In contrast, the second hypothesis focuses on vascular 'underfilling' due to inappropriately low aldosterone levels. 6, 31 Although aldosterone levels in pregnancy are controlled by salt intake, we did not measure the urinary sodium excretion or the salt ingestion in our patients, which is rather high in our population, calculated close to 4 g per day. 32 It is important to underline that this is the first study analysing the relationship of the -344C/T polymorphism of the aldosterone synthase CYP11B2 gene with the serum aldosterone concentration in women with gestational hypertension. There is only one earlier report analysing the relationship of the -344C/T polymorphism of the aldosterone synthase CYP11B2 gene with gestational hypertension, although the authors did not evaluate aldosterone levels. 19 All other studies have been done in preeclamptic women. 6, [18] [19] [20] It is also of interest to observe the presence of the MR 810L mutation of the MR in both the hypertensive pregnant (12%) and the normotensive pregnant women (9.4%); in line with our results, further studies should be done genotyping the MR 810L mutation in preeclamptic women, as well as in the local general population.
In conclusion, our data do not support the relationship of gestational hypertension with the -344C/T polymorphism of the aldosterone synthase CYP11B2 gene, or with the MR L810 mutation of the MR gene. Further studies will be necessary to explore the contribution of the intron 2 conversion polymorphism to the development of risk gestational hypertension, examining other genetic polymorphisms and vascular factors to explain the decrease of the aldosterone levels in women with gestational hypertension.
